drugset / Trial / NCT03688269

Minimal Effective Concentration (EC90) of Ropivacaine

NCT03688269

Phase 3 Completed 146 enrolled Centre Hospitalier Universitaire de Besancon
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Prospective up and down sequential evaluation of the minimal effective concentration of perineural ropivacaine for 90% success in axillary brachial plexus block with the injection of intravenous dexamethasone or saline placebo during regional anesthesia performance

Timeline

Start
2018-10-05
Primary completion
2019-11-04
Completion
2020-05-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 8 mg Intravenous
Subject Ropivacaine Other / unclassified 20 ml Other

Indications

No indication recorded.